FDA Approves New Antibiotic Zevtera for Treating Bacterial Infections

FDA approved the antibiotic Zevtera for treating 3 infections Staphylococcus aureus bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia in adults and children.

In clinical trials, Zevtera was as effective as comparator antibiotics in treating the 3 infections.

The most common side effects of Zevtera include nausea, vomiting, diarrhea, increased liver enzymes, and rash.

Zevtera was granted Priority Review, Fast Track and Qualified Infectious Disease Product designations from the FDA.

The FDA granted approval of Zevtera to Basilea Pharmaceutica International Ltd.